![](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a0/Variety_of_glycans.svg/440px-Variety_of_glycans.svg.png)
In the field of biochemistry, N-linked glycosylation is the attachment of a sugar molecule (known as glycan) to an amide nitrogen of asparagine (Asn) residue of a protein, giving rise to a glycoprotein. This type of linkage is important for both the structure [1] and function [2] of some eukaryotic proteins. The N-linked glycosylation process occurs in eukaryotes and widely in archaea, but very rarely in prokaryotes. The nature of N-linked glycans attached to a glycoprotein is determined by the protein and the cell in which it is expressed.[3] It also varies across species. Different species synthesises different types of N-linked glycoproteins.
Bond formation and Energetics
editThere are two types of bonds involved in a glycoprotein: bonds between the saccharides residues in the glycan and the linkage between the glycan chain and the protein molecule.
The sugar moieties are linked to one another in the glycan chain via glycosidic bonds. These bonds are formed between carbon 1 and 4 of the sugar molecules. The formation of glycosidic bond is energetically unfavourable, therefore the reaction is coupled to the hydrolysis of two ATP molecules.[3]
On the other hand, the attachment of a glycan residue to a protein requires the recognition of a consensus sequence. N-linked glycans are almost always attached to the nitrogen atom of an Asn side chain that is present as a part of Asn-X-Ser/Thr consensus sequence, where X is any amino acid except proline.[3]
In animal cells, the glycan attached to the Asn is almost inevitably, N-Acetylglucosamine (GlcNAc), in the β-configuration.[3] This β-linkage is similar to glycosidic bond between the sugar moieties in the glycan structure as described above. The anomeric carbon atom instead of being attached to a sugar hydroxyl group is attached to amide nitrogen. The energy required for this linkage comes from the hydrolysis of a pyrophosphate molecule.[3]
Pathway of N-linked glycan biosynthesis
editThe biosynthesis of N-linked glycans occurs via 3 major steps[3]
- Synthesis of dolichol-linked precursor oligosaccharide
- En block transfer of precursor oligosaccharide to protein
- Processing of the oligosaccharide
Synthesis, en bloc transfer and initial trimming of precursor oligosaccharide occurs in the Endoplasmic Reticulum (ER). Whereas, subsequent processing and modification of the oligosaccharide chain is carried out in the Golgi apparatus.
The synthesis of glycoproteins is thus, spatially separated in different cellular compartments. Therefore, the type of N-glycan synthesised depends on the accessibility of the glycan to the different enzymes present within these cellular compartments.
However, in spite of the diversity, all N-glycans are synthesised through a common pathway with a common core glycan structure.[3]
The core glycan structure consist of two N-Acetyl Glucosamine and three mannose residues. These core glycan is then elaborated and modified further, resulting in a diverse range of N-glycan structures.[3]
Synthesis of precursor oligosaccharide
editThe process of N-linked glycosylation starts with the formation of dolichol-linked sugar (GlcNAc). Dolichol is a lipid molecule composed of repeating isoprene units. This molecule is found attached to the membrane of the ER. Sugar molecules are attached to the dolichol through a pyrophosphate linkage[3] (One phosphate was originally linked to dolichol, and the second phosphate came from the nucleotide sugar). The oligosaccharide chain is then extended through the addition of various sugar molecules in a step-wise manner to form a precursor oligosaccharide.
The assembly of this precursor oligosaccharide essentially occurs in two phases: Phase I and II.[3] Phase I takes place on the cytoplasmic side of the ER and Phase II takes place on the luminal side of the ER.
The precursor molecule, ready to be transferred to a protein, consist of 2 GlcNAc, 9 mannose and 3 glucose moieties.
|
|
| |
Phase II | |
|
En bloc transfer of glycan to protein
editOnce the precursor oligosaccharide is formed, the completed glycan is then transferred to the nascent polypeptide in the lumen of the ER membrane. This reaction is driven by the energy released from the cleavage of the pyrophosphate bond between the dolichol-glycan molecule. There are three conditions to fulfill before a glycan is transferred to a nascent polypeptide[3]:
- Asn must be located in a specific consensus sequence in the primary structure (Asn-X-Ser or Asn-X-Thr or in rare instances Asn-X-Cys).[4]
- Asn must be located appropriately in the three dimensional structure of the protein (Sugars are polar molecules and thus need to be attached to Asn located on surface of the protein and not buried within the protein)
- Asn must be found in the luminal side of the ER for N-linked glycosylation to be initiated. (Target Asn residues are either found in secretory proteins or in the regions of transmembrane protein that faces the lumen.)
Oligosaccharyltransferase is the enzyme responsible for the recognition of the consensus sequence and the transfer of the precursor glycan to a polypeptide acceptor which is being translated in the ER lumen. N-linked glycosylation is therefore, is a co-translational event
Processing of glycan
editN-glycan processing is carried out in ER and the Golgi. Initial trimming of the precursor molecule occurs in the ER and the subsequent processing occurs in the Golgi.
Upon transferring the completed glycan onto the nascent polypeptide, three glucose residues are removed from the structure. Enzymes known as glycosidases remove some sugar residues. These enzymes can break glycosidic linkages by using a water molecule. These enzymes are exoglycosidases as they only work on monosaccharide residues located at the non-reducing end of the glycan.[3] This initial trimming step is thought to act as a quality control step in the ER to monitor protein folding.
Once protein is folded correctly, the three glucose residues are removed by Glucosidase I and II. The removal of the final glucose residue signals that the glycoprotein is ready for transit from the ER to the cis-Golgi.[3] However, if the protein is not folded properly, the glucose residues are not removed and thus the glycoprotein can’t leave the ER. A chaperone protein (Calnexin/Calreticulin) binds to the unfolded or partially folded protein to assist protein folding.
The next step involves further addition and removal of sugar residues in the golgi. These modifications are catalyzed by glycosyltransferases and glycosidases respectively. In the cis-golgi, a series of mannosidases remove some or all of the four mannose residues in alpha 1,2 linkages.[3] Whereas, in the medial portion of golgi, glycosyltransferases add sugar residues, to the core glycan structure giving rise to the three main types of glycans: high mannose, hybid and complex glycans.
- High-mannose is, in essence, just two N-Acetylglucosamines with many mannose residues, often almost as many as are seen in the precursor oligosaccharides before it is attached to the protein.
- Complex oligosaccharides are so named because they can contain almost any number of the other types of saccharides, including more than the original two N-Acetylglucosamines.
- Hybrid oligosaccharides contain a mannose residues on one side of the branch, while on the other side a N-Acetylglucosamine initiates a complex branch.
The order of addition of sugars to the growing glycan chains is determined by the substrate specificities of the enzymes and their access to the substrate as they move through secretory pathway. Thus, the organization of this machinery within a cell plays an important role in determining which glycans are made.
Organization of enzymes in the Golgi
editGolgi enzymes plays a key role in determining the synthesis of the various types of glycan. The order of action of the enzymes is reflected in their position in the Golgi stack:
Enzymes | Location within Golgi |
---|---|
Mannosidase I | cis-Golgi |
GlcNAc transferases | medial Golgi |
Galactosyltransferase and Sialyltransferase | trans-Golgi |
Biosynthesis pathway comparison to archaea and prokaryotes
editSimilar N-glycan biosynthesis pathway have been found in prokaryotes and Archaea[5]. However, compared to eukaryotes, the final glycan structure in prokaryotes and Achaea does not seem to differ much from the initial precursor made in the ER. In eukaryotes, the original precursor oligosaccharide is extensively modified en route to the cell surface.[3]
Functions of N-glycans
editN-linked glycans have intrinsic and extrinsic functions[3].
Intrinsic |
|
Extrinsic |
|
Clinical significance
editMutations in eighteen genes involved in N-linked glycosylation result in a variety of diseases, most of which involve the nervous system.[2]
Importance in therapeutic proteins
editMany “blockbuster” therapeutic proteins in the market now are N-linked glycoproteins. For examples Etanercept, Infliximab and Rituximab are N-glycosylated therapeutic proteins.
The importance of N-linked glycosylation is becoming increasingly evident in the field of pharmaceuticals. Proteins are usually produced using bacterial or yeast protein expression systems due to high yield and low cost, however, problems arise when the desired protein is glycosylated in its native state. Most prokaryotic expression systems such as E.coli cannot carry out post-translational modifications. Eukaryotic expression hosts such as yeast and animal cells on the other hand, have different glycosylation patterns. The proteins produced in these expression hosts are often not identical to human protein and thus, causes immunogenic reactions in patients. For example S.cerevisiae (yeast) often produce high-mannose glycans which are immunogenic.
Animal expression systems on the other hand, have the machinery required to carry out complex glycosylation process but their glycans differ from human glycans in their terminal sugar molecule. The glycans in animal cells are cappped with N-Glycolylneuraminic acid (Neu5Gc) instead of N-Acetylneuraminic acid (Neu5Ac) (humans).
Studies are being conducted to tackle this problem in protein expression. Among the efforts being taken to produce therapeutic glycoproteins with human-like N-linked glycoproteins includes using CHO cell line and glycoengineered Pichia pastoris[7]( a type of yeast) as expression hosts.
See also
editReferences
edit- ^ Imperiali B, O'Connor SE (December 1999). "Effect of N-linked glycosylation on glycopeptide and glycoprotein structure". Curr Opin Chem Biol. 3 (6): 643–9. doi:10.1016/S1367-5931(99)00021-6. PMID 10600722.
- ^ a b Patterson MC (September 2005). "Metabolic mimics: the disorders of N-linked glycosylation". Semin Pediatr Neurol. 12 (3): 144–51. doi:10.1016/j.spen.2005.10.002. PMID 16584073.
- ^ a b c d e f g h i j k l m n o p Drickamer K, Taylor ME (2006). Introduction to Glycobiology (2nd ed.). Oxford University Press, USA. ISBN 978-0-19-928278-4.
- ^ Mellquist JL, Kasturi L, Spitalnik SL, Shakin-Eshleman SH (May 1998). "The amino acid following an asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency". Biochemistry. 37 (19): 6833–7. doi:10.1021/bi972217k. PMID 9578569.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Anne Dell (8 November 2010). "Similarities and Differences in the Glycosylation Mechanisms in
Prokaryotes and Eukaryotes". International Journal of Microbiology. (2010): 1–14. doi:10.1155/2010/148178. PMID 148178.
{{cite journal}}
: line feed character in|title=
at position 64 (help)CS1 maint: unflagged free DOI (link) - ^ Steve Elliott (August 2005). "Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins". Journal of Pharmaceutical Sciences. 94 (8): 1626–1635. doi:10.1002/jps.20319. PMID 1002.
- ^ Stephen R. Hamilton (29 August 2003). "Production of Complex Human Glycoproteins in Yeast". Science. 301 (5637): 1244–1246. doi:10.1126/science.1088166. PMID 1088166.